Clinical implications for BRCA gene mutation in breast cancer

Jin Xu,Baosheng Wang,Yanjun Zhang,Ruihui Li,Yuehua Wang,Shaokun Zhang

DOI: https://doi.org/10.1007/s11033-011-1073-y

IF: 2.7422

2011-06-21

Molecular Biology Reports

Abstract:To investigate the mutations of BRCA1 and BRCA2 and determine whether clinic-pathological factors related to BRCA gene mutation. Mastectomy specimens from 360 breast cancers were enrolled and examined in the study. The relationship between BRCA gene mutation and clinic-pathological factors was evaluated. Overall, 280 patients were BRCA negative and 80 got BRCA gene mutation. Triple-negative breast cancers—i.e., breast cancers that do not express estrogen receptors (ER), progesterone receptors (PR) or human epidermal growth factor receptor 2 (HER2/neu)—was observed in 53.85% of the BRCA1 mutation patients, in 28.57% of the BRCA2 mutation cases, while 14.29% of BRCA negative patients. BRCA1 mutation patients got a heavy lymph node metastasis and higher nuclear grade tumors than the others (P = 0.004, 0.007). Furthermore, BRCA mutation was also found to be significantly related to ER, PR and HER2/neu status (P < 0.05). BRCA1 expression was not associated with breast cancer-specific survival in the triple-negative breast cancers (P = 0.742). After Cox regression, BRCA1 mutation was not shown to be an independent prognostic factor for breast cancer. These findings substantiated the possibility of tumors associated with BRCA1 mutations divided into two distinct groups, triple-negative and non-triple-negative groups requires further investigation.

biochemistry & molecular biology

What problem does this paper attempt to address?

This paper aims to explore the BRCA1 and BRCA2 gene mutations in breast cancer and evaluate the relationship between these mutations and clinicopathological factors. Specifically, the researchers investigated the presence of BRCA1 and BRCA2 gene mutations and whether these mutations were associated with specific clinicopathological features, such as triple - negative breast cancer (breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor receptor 2 (HER2/neu)), lymph node metastasis, and tumor nuclear grade, etc., by analyzing mastectomy specimens from 360 breast cancer patients. In addition, the study also explored the relationship between BRCA gene mutation status and breast - cancer - specific survival rate.

Through this study, the authors hope to understand the clinical significance of BRCA gene mutations in breast cancer, especially how these mutations affect patients' prognosis and treatment options. This not only helps to better understand the role of BRCA gene mutations in the development of breast cancer, but also provides an important reference for personalized medicine.